Table 1 Administration information
Title {1} | Oral nicotinamide mononucleotide (NMN) as a treatment for chronic insomnia: protocol for the multicenter, randomized, double-blind, placebo-controlled trial |
|---|---|
Trial registration {2a and 2b} | Chinese Clinical Trial Registry (chictr.org.cn): ChiCTR2200058001. Registered on 26 March 2022. ChiCTR2200058001 |
Protocol version {3} | 13 March 2022. Version 1 |
Funding {4} | This trial is funded by grants from China Health Promotion Foundation |
Author details {5a} | Xiangyang Gao, Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China Junhua Li, Health Management Center, Handan Central Hospital, Handan, Hebei Province, China Sanping Xu, Health Management Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province China Xueying Li, Department of Biostatistics, Peking University First Hospital, Beijing 100,034, China Xicheng Wang, Beijing Dublin International Collage, Beijing University of Technology, Beijing 100,124, China Yongli Li, Health Management Center, Henan Provincial People's Hospital, Zhengzhou, China Yan Huang, Health Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China Shaohui Liu, Health Management Center, Xiangya Hospital, Central South Hospital, Changsha, Hunan Province, China Qiang Zeng, Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China XYG and ZQ are the Chief Investigators who conceived the study, led the proposal and protocol development. JHL, SPX, XYL, XCW, YLL, SHL, and HY all contributed to the trial design and to development of the proposal. XYL and XCW are lead trial methodologist. All authors read and approved the final protocal manuscript |
Name and contact information for the trial sponsor {5b} | This trial is funded and proceeded by China Health Promotion Foundation Wu Shiyong, Room 521,Wankai Road, Fentai District, Beijing, China, + 86–13,261,008,988, Email: 82,125,586@qq.com |
Role of sponsor {5c} | This trial is solely funded by non-commercial sources. Funding sources have had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results |